– USA, AZ – Calviri, Inc. today announced the appointment of Michael Chambers to its Board of Directors. Until recently Chambers held the position of CEO at Aldevron (Fargo, ND) where he remains Chairman of the Board.
“I have known Michael for over 20 years and have been amazed at what he has accomplished at Aldevron. We are confident his expertise and experience will be of great value to Calviri and I look forward to working together with him,” said CEO, Stephen Johnston.
An entrepreneur at heart, Chambers founded Aldevron over 20 years ago and grew the company from 2 to 600 employees to become the major supplier of DNA, RNA, antibodies, and proteins to the research and clinical communities. It operates the largest DNA production facility in the world.
Aldevron manufactured the vaccine currently being used in Calviri’s preventative cancer vaccine trial, VACCS. Chambers’ broad experience and success in the biotechnology industry will contribute greatly to new trials as Calviri works toward its diagnostic and vaccine product goals.
Calviri is focused short-term on producing human and animal cancer diagnostic products using novel Frame Shift Peptides and Immunosignature Platform technologies. Its long-term goal is to develop therapeutic and preventative cancer vaccines to achieve the ultimate mission in the industry: to end deaths from cancer.
“I am excited to be part of Calviri. This team’s vision, technology and commitment are a winning combination,” commented Chambers.
About Calviri, Inc.
Calviri is an early-stage healthcare company whose mission is to provide a broad spectrum of fundamentally different vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. Calviri is focused on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer.
The company is a spin-out of the Biodesign Institute, Arizona State University, located in Tempe, AZ.
For more information: https://calviri.com/
About Aldevron
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source quality system. Company headquarters are in Fargo, ND, with additional facilities in Madison, WI, and Freiburg, Germany.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
